Currently Viewing:
American Diabetes Association (ADA) 2017
Dr Alan Carter on Biosimilars in the Insulin Market
July 27, 2017
Dr Eda Cengiz on New Technologies in Diabetes Management
July 26, 2017
Robby Booth of Glytec Discusses the Importance of Data-Sharing Capabilities
July 24, 2017
Dr Andrew Rhinehart: Improving Intermediate Outcomes in Diabetes Research
July 20, 2017
WellDoc Data Offer Promise for Integrating Diabetes Data Into Workflow
July 17, 2017
Dr Alan Carter on the Steps to Managing Rising Insulin Costs
July 17, 2017
Dr Eda Cengiz Discusses the Future of Diabetes Management
July 13, 2017
Nina Brown-Ashford: DPP Will Improve Care and Costs for Prediabetes Patients
July 06, 2017
Dr Alan Carter on Increasing Insulin Costs
July 04, 2017
Dr William Polonsky on Diabetes Patients' Treatment Satisfaction and Insulin Adherence
June 29, 2017
Dr Eda Cengiz on Improvements in Closed-Loop Systems
June 26, 2017
With Glytec, Hospital Moves to Basal-Bolus Insulin, Saves $9.7 Million
June 21, 2017
Raymie McFarland Discusses Findings From Glytec's Basal-Bolus Insulin Study
June 21, 2017
Sanofi Presents New Results for Insulin GLP-1 Combo Soliqua
June 13, 2017
Dr Bruce Neal Discusses Canagliflozin's Potential for Heart Failure Prevention
June 13, 2017
Dr Eda Cengiz Explains Artificial Pancreas Systems' Implications for Patients and Clinicians
June 13, 2017
CGM "Debate" Finds Benefits, Barriers to Uptake for Type 2 Diabetes
June 12, 2017
CANVAS Finds Lower Risk of CV Events for Invokana
June 12, 2017
Phase 3 Results Show Lower A1C for Ertugliflozin, Combined With Metformin and With Sitagliptin
June 12, 2017
Currently Reading
Heart Failure Needs More Attention in Diabetes Drug Trials, Expert Says
June 11, 2017

Heart Failure Needs More Attention in Diabetes Drug Trials, Expert Says

Mary Caffrey and Angelia Szwed
At a symposium at the 77th Scientific Sessions of the American Diabetes Association, experts suggested that the relationship between heart failure and diabetes is finally getting the attention it deserves.
The effect of drugs to treat diabetes on heart failure should be front and center in clinical trials, according to an expert at a symposium on the relationship between the 2 conditions at the 77th Scientific Sessions of the American Diabetes Association (ADA), held Saturday in San Diego, California.

Ten years ago this week, the New England Journal of Medicine’s article on rosiglitazone stunned the diabetes and cardiovascular treatment communities alike, when it connected a blockbuster glucose-lowering therapy with deaths from heart attacks. The incident led to an FDA guidance requiring pharmaceutical companies to study the effects of all new diabetes and obesity therapies for their effects on cardiovascular events and mortality.

In a sign of how much the fields are overlapping, 3 months ago leading researchers in diabetes attended the American College of Cardiology (ACC) to discuss plans for EMPEROR HF, which will study emagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in heart failure patients, including those without diabetes. And yesterday, at the symposium, “Diabetes, Drugs, and Heart Failure,” leading cardiologists took the podium, led by Darren K. McGuire, MD, MHSc, of the University of Texas Southwestern.

The cardiologists speaking at ADA asserted that heart failure, perhaps, is finally getting its due, given its $31 billion footprint on the healthcare system and its rising cost to Medicare. While 25% of those newly diagnosed with heart failure have diabetes, according to Shannon Dunlay, MD, MS, of Mayo Clinic, they tend to be sicker, accounting for 46% of heart failure hospitalizations. “This is an area we need to learn more about,” she said.

Eldrin F. Lewis, MD, MPH, of Brigham and Women’s Hospital, was more blunt in his talk that called for making heart failure a primary endpoint in cardiovascular outcomes trials, not a “secondary, or exploratory, or not even looked at endpoint.”

When scrutinizing heart failure hospitalization rates in drug trials, he said it’s essential to examine what happens to these patients afterward—death rates can be high. Looking at data for saxagliptin, which had shown a heart failure hospitalization signal that FDA examined, Lewis said, “I would rather not be joining the heart failure club.”

While Dunlay said studies have linked diabetes and heart failure for decades—going back to the Framingham Heart Study in 1974—there’s still much that isn’t known. The pathway from diabetes to heart failure “is circuitous and still ill-defined,” she said.

What is known: “If you have diabetes in the presence of heart failure, you do worse,” Dunlay said.” Diabetes increases death from heart failure by 50%; although patients with diabetes ultimately die of the same causes as other heart failure patients, she said, they die earlier.



 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!